Research programme: tumour necrosis factor/interleukin 6 inhibitor - Bone MedicalAlternative Names: BN 006
Latest Information Update: 26 Jan 2016
At a glance
- Originator Bone Medical
- Developer Bone Medical; Institute of Bone & Joint Research; William Harvey Research Institute
- Class Antirheumatics; Peptides
- Mechanism of Action Interleukin 6 inhibitors; Macrophage inhibitors; Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Suspended Rheumatoid arthritis